Slide 1: Innovating for the healthcare needs of today and tomorrow
1 Innovating for the healthcare needs of today and tomorrow Q3 presentation 12 November 2015
Slide 2: Antibiotic resistance and healthcare associated infections at the top of the political agenda
2 Antibiotic resistance and healthcare associated infections at the top of the political agenda Global consumption of antibiotics increased by 30 percent between 2000 and 2010, from approximately 50 billion to 70 billion standard units, based on data from 71 countries. CDDEP report ”The State of the
Slide 3: Focus and priorities
3 Focus and priorities Key priorities • Refinancing of bond loan • Developing new license businesses • Driving sales of our own portfolio Achievements and actions • Credit facility in place • Entering new therapeutic area through license agreement • Strengthening the sales team and focusing on key m
Slide 4: Third quarter in brief
4 Third quarter in brief • Additional order of MSEK 28 from C.R. Bard, with positive effect on revenues, results and cash flow • Underlying business with C.R. Bard remains stable • Slow quarter with weak performance in sales of our BIP portfolio • Repeat orders from the Middle East • 40 ongoing eval
Slide 5: Focus potential markets and regions
5 Market update Focus Focus on select marketson andhigh potential generating markets and regions repeat orders EUROPE • Focus on select markets • Strengthening of the team • 40 ongoing evaluations in Sweden MEA ASIA • Focus on generating • Preparations for launch repeat orders in Pakistan • GCC tend
Slide 6: Bactiguard's clinical evidence is getting even stronger
6 Bactiguard’s clinical evidence is getting even stronger 140 million Foley catheters have been used since 1995 35% of weighted average reduction is proven in clincial studies of symptomatic CAUTI (catheter associated urinary tract infections), but in some studies up to 70% 50% reduction of catheter
Slide 7: Clinical evidence BIP Foley: Fabrellas et al, 2015
7 Clinical evidence BIP Foley: Fabrellas et al, 2015 % infected Number of patients 116 30,0 Patients Cardiac surgery post- 25,0 -38 % operative patients OR=2.22, 20,0 p=0.037 Design Prospective randomized 15,0 Hospital/Country Spain 10,0 Primary outcome UTI confirmed by 105 CFU/ml microorganisms in
Slide 8: Clinical evidence BIP ETT: Tincu et al, 2015
Clinical evidence-ETT 8 Bucharest BIP ETTClinical TincuEmergency et al, 2015Hospital, University of Medicine and Pharmacy “Carol Davila”, Critical Care Toxicology Unit, Bucharest, Romania (presented as poster, Euroanasthesia 2015) 20 18% No of patients 100 18 (p>0.05) Intubation 5 days 16 67% time 1
Slide 9: Revenue streams
9 Revenue streams Three revenue streams in the income statement License BIP portfolio Bard license deal BIP Foley BIP ETT BIP CVC (sales since 1995) 1 2 3 License Territorial fee BIP revenue From a product perspective Bactiguard has two lines of business; Licenses and the BIP portfolio, acknowledged
Slide 10: Highlights
Highlights Financial overview 10 Highlights Third quarter (July-September 2015) • Revenues of MSEK 61.4 (28.1), plus 118% compared to 2014 • EBITDA of MSEK 33.9 (2.2), 55% margin Positive change mainly attributable to additional order in Q3 from C.R. Bard Nine-months (January-September 2015) •Revenu
Slide 11: Supplied products
Supplied products Financial overview 11 Supplied products • 15 000 BIP products supplied in Q3 2015 compared to approx. 12 000 during Q3 2014 • For the first nine months 2015, 78 000 BIP products were supplied compared to 71 000 for the corresponding period in 2014, an increase of approx. 10% • For
Slide 12: Income distribution
Income distribution Financial overview 12 Income distribution Jul-Sep Jul-Sep Jan-Sep MSEK 2015 2014 2015 License revenues 56,8 24,3 109,4 Territorial fees - 0,6 - Sales of BIP products 0,6 0,5 1,7 Other revenue 4,1 2,6 6,9 Total Revenues 61,4 28,1 118,0
Slide 13: License revenues from C.R. Bard
License revenues from C.R. Bard Financial overview 13 License revenues License revenues (SEKm) Q1 Q2 H1 Q3 Q4 9 mths Full year Of which 2013 21,6 19,3 40,9 21,3 20,5 62,2 82,7 currency effect 2014 22,5 22,8 45,3 24,3 20,2 69,6 89,8 MSEK 4 m 2015 26,8 25,8 52,6 56,8 109,4 Of which currency effect MSE
Slide 14: Key figures
Key figures Financial overview 14 Key figures Jul-Sep Jul-Sep Jan-Sep Key figures • EBITDA (Q3) MSEK 33.9, 2015 2014 2015 Revenues, SEKm 61,4 28,1 118,0 EBITDA, SEKm 33,9 2,2 -2,9 • EBITDA (Nine-months) MSEK EBITDA margin, % 55% 8% -2% -2.9, adjusted EBITDA EBITDA*, SEKm 33,9 2,2 -2,9 MSEK 32.5. EBI
Slide 15: Financial flexibility and strength
Financial flexibility and strength Financial overview 15 Financial flexibility and strength Q2 -14 Share issue of MSEK 20 in April Set off issue of MSEK 222.5 in June Share issue of MSEK 240 in connection with IPO Q2 -14 • Repurchase of bonds, nominal value MSEK 88.5 - Q3 15 • Equity ratio of
Slide 16: Financial targets
16 Financial targets • Previous targets have been based on an average sales growth of at least 30% per annum over a five-year period, with base year 2013. Revised financial targets Average sales growth of 20% per annum for a 5-year period, with 2015 (adjusted for the additional order from C.R. Bar
Slide 17: Key take aways
17 Key take aways • Focus on select markets and generating repeat orders • Developing license business and entering new therapeutic areas • Clinical evidence is getting even stronger • One off order from C.R. Bard had a positive effect on revenues and cash flow, stable underlying business • Revenues
Slide 18: More information is available on our website
18 More information is available on our webiste www.bactiguard.se For questions and additional information, please contact: Christian Kinch, CEO: +46 8 440 58 80 Christian.kinch@bactiguard.se Fredrik Järrsten, CFO: +46 725 500 089 fredrik.jarrsten@bactiguard.se Cecilia Edström, Vice President- Direc
Slide 19: Questions
19 Bactiguard has an important role to play Preventing healthcare associated infections Questions